{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:49:39Z","timestamp":1792050579206,"version":"4.4.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>To address high out-of-pocket (OOP) medication costs among Medicare Part D beneficiaries, the 2022 Inflation Reduction Act introduced the Medicare Prescription Payment Plan (M3P), a voluntary program that allows beneficiaries to spread OOP costs over the calendar year. We examined M3P's potential impact among beneficiaries with cancer, who frequently incur substantial early-year Part D medication costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>We evaluated a 2022 5% random sample of Medicare beneficiaries with a cancer diagnosis and \u22651 fill for a cancer-indicated Part D medication. We estimated 2025-adjusted annual true OOP spending and median monthly beneficiary OOP payment obligations with and without M3P enrollment. Subgroup analyses were performed by demographics, nonadherence status in 2022, and Part D benefit phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Among 168,480 beneficiaries with cancer, most were diagnosed with breast (47.6%), dermatologic (17.6%), or prostate (13.3%) cancers. Overall, 46.7% were projected to reach catastrophic coverage in 2025, with 32.4% doing so in January. Breast (29.7%), prostate (21.20%), and hematologic (20.0%) cancers were most common among those reaching catastrophic coverage. Overall, 43.0% were nonadherent to cancer-indicated Part D medications, with 31.5% reaching catastrophic coverage in January 2025. M3P reduced beneficiary payment obligation variability, especially among those reaching the catastrophic phase in January (IQR, $1,798 US dollars [USD] no M3P\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      $118 USD M3P). Of those reaching catastrophic coverage with a cancer-indicated drug (58.6% overall), 89.2% did so in January.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Early-year entry into catastrophic coverage is common among beneficiaries with certain high-cost cancers. M3P may most effectively reduce financial burden when enrollment occurs before January. Targeted outreach from cancer care teams and Part D plans to nonadherent patients and those considering costly therapies could maximize program impact and improve treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-01788","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:59:44Z","timestamp":1768510784000},"page":"598-606","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Potential Impact of the Medicare Prescription Payment Plan for Medicare Part D Beneficiaries With a Cancer Diagnosis"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1842-0174","authenticated-orcid":true,"given":"Aryana","family":"Sepassi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice &amp; Sciences, University of California, San Diego Skaggs School of Pharmacy &amp; Pharmaceutical Sciences, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-8280","authenticated-orcid":true,"given":"Scott D.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mark","family":"Fendrick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of General Medicine, University of Michigan, School of Medicine, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice &amp; Sciences, University of California, San Diego Skaggs School of Pharmacy &amp; Pharmaceutical Sciences, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2661-904X","authenticated-orcid":true,"given":"Jason A.","family":"Zell","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4147-5785","authenticated-orcid":true,"given":"Dana B.","family":"Mukamel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Internal Medicine, iTEQC Research Program, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, School of Pharmacy, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","volume-title":"Cancer Facts & Figures 2024","unstructured":"Cancer Facts & Figures 2024. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2024-cancer-facts-figures.html"},{"key":"e_1_3_7_3_2","volume-title":"July2023_MedPAC_DataBook_SEC.pdf","unstructured":"July2023_MedPAC_DataBook_SEC.pdf. https:\/\/www.medpac.gov\/wp-content\/uploads\/2023\/07\/July2023_MedPAC_DataBook_SEC.pdf"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.2476"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1534"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.21468"},{"key":"e_1_3_7_7_2","first-page":"s78","article-title":"High cost sharing and specialty drug initiation under Medicare Part D: A case study in patients with newly diagnosed chronic myeloid leukemia","volume":"22","author":"Doshi JA","year":"2016","unstructured":"Doshi JA, Li P, Huo H, et al: High cost sharing and specialty drug initiation under Medicare Part D: A case study in patients with newly diagnosed chronic myeloid leukemia. Am J Manag Care 22:s78-s86, 2016 (suppl 4). https:\/\/www.ajmc.com\/view\/high-cost-sharing-and-specialty-drug-initiation-under-medicare-part-d-a-case-study-in-patients-with-newly-diagnosed-cml","journal-title":"Am J Manag Care"},{"key":"e_1_3_7_8_2","volume-title":"1 in 5 Medicare Beneficiaries Taking a Part D Cancer Therapy Reached Catastrophic Level in 2017","author":"Meyer T","year":"2019","unstructured":"Meyer T, Stengel K: 1 in 5 Medicare Beneficiaries Taking a Part D Cancer Therapy Reached Catastrophic Level in 2017. Avalere Health Advisory, 2019. https:\/\/advisory.avalerehealth.com\/insights\/one-in-5-medicare-beneficiaries-taking-a-part-d-cancer-therapy-reached-catastrophic-level-in-2017"},{"key":"e_1_3_7_9_2","first-page":"S39","article-title":"Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: Addressing the problem of \u201ctoo much too soon.\u201d","volume":"23","author":"Doshi JA","year":"2017","unstructured":"Doshi JA, Li P, Pettit AR, et al: Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: Addressing the problem of \u201ctoo much too soon.\u201d Am J Manag Care 23:S39-S45, 2017 (suppl 3)","journal-title":"Am J Manag Care"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5091"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.21270"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.014639"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.8.831"},{"key":"e_1_3_7_15_2","volume-title":"Rep. Yarmuth JA [D K 3. Text - H.R.5376 - 117th Congress (2021-2022): Inflation Reduction Act of 2022","year":"2022","unstructured":"Rep. Yarmuth JA [D K 3. Text - H.R.5376 - 117th Congress (2021-2022): Inflation Reduction Act of 2022. 2022. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text"},{"key":"e_1_3_7_16_2","volume-title":"Income and Assets of Medicare Beneficiaries in 2023","author":"Cottrill A","unstructured":"Cottrill A, Cubanski J, Neuman T, et al: Income and Assets of Medicare Beneficiaries in 2023. KFF. https:\/\/www.kff.org\/medicare\/issue-brief\/income-and-assets-of-medicare-beneficiaries-in-2023\/"},{"key":"e_1_3_7_17_2","unstructured":"Milliman Medicare Market Intelligence: MedIntel insights: Early look at Medicare prescription payment plan enrollment. https:\/\/www.milliman.com\/en\/insight\/medintel-insights-early-look-m3p-enrollment"},{"key":"e_1_3_7_18_2","unstructured":"Office of the Assistant Secretary for Planning and Evaluation (ASPE): Inflation Reduction Act research series: Medicare Part D enrollee out-of-pocket spending: Recent trends and projected impacts of the Inflation Reduction Act. https:\/\/aspe.hhs.gov\/reports\/medicare-part-d-enrollee-out-pocket-spending"},{"key":"e_1_3_7_19_2","unstructured":"Centers for Medicare and Medicaid Services: 2022 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. https:\/\/www.cms.gov\/files\/document\/2022-medicare-trustees-report.pdf"},{"key":"e_1_3_7_20_2","volume-title":"Social Vulnerability Index","author":"CDC","year":"2024","unstructured":"CDC: Social Vulnerability Index. Place and Health\u2014Geospatial Research, Analysis, and Services Program (GRASP), 2024. https:\/\/www.atsdr.cdc.gov\/place-health\/php\/svi\/index.html"},{"key":"e_1_3_7_21_2","volume-title":"Total Number of Medicare Beneficiaries by Type of Coverage","unstructured":"Total Number of Medicare Beneficiaries by Type of Coverage. KFF. https:\/\/www.kff.org\/medicare\/state-indicator\/total-medicare-beneficiaries\/"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjdsi.2018.01.001"},{"key":"e_1_3_7_23_2","volume-title":"A Brave New World: Medicare's $2,000 Cap, A Tectonic Shift Pharma Can't Afford to Miss","unstructured":"A Brave New World: Medicare's $2,000 Cap, A Tectonic Shift Pharma Can't Afford to Miss. https:\/\/www.iqvia.com\/locations\/united-states\/blogs\/2025\/07\/a-brave-new-world-medicares-2000-cap"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.07.003"},{"key":"e_1_3_7_25_2","unstructured":"Centers for Medicare and Medicaid Services: Medicare prescription payment plan: Final part two guidance. https:\/\/www.cms.gov\/files\/document\/medicare-prescription-payment-plan-final-part-two-guidance.pdf"},{"key":"e_1_3_7_26_2","article-title":"Reducing Medicare Part D out-of-pocket costs for specialty oral anticancer drugs under the inflation reduction act: Highlighting the benefits of enrolling in the Medicare prescription payment plan","author":"Doshi JA","unstructured":"Doshi JA, Li P, Asthana S, et al: Reducing Medicare Part D out-of-pocket costs for specialty oral anticancer drugs under the inflation reduction act: Highlighting the benefits of enrolling in the Medicare prescription payment plan. JCO Oncol Pract 10.1200\/OP-24-00937","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.12.1750"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.01742"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06415-8"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0151-3"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6029097"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.28_suppl.180"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00665"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35721"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz183"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:01:05Z","timestamp":1772924465000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1200\/JCO-25-01788"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01788","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"2025-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}